Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 232

1.

Female mice with apolipoprotein E4 domain interaction demonstrated impairments in spatial learning and memory performance and disruption of hippocampal cyto-architecture.

Adeosun SO, Hou X, Shi L, Stockmeier CA, Zheng B, Raffai RL, Weisgraber KH, Mosley TH, Wang JM.

Neurobiol Learn Mem. 2019 May;161:106-114. doi: 10.1016/j.nlm.2019.03.012. Epub 2019 Apr 4.

PMID:
30954674
2.

Cognitive deficits and disruption of neurogenesis in a mouse model of apolipoprotein E4 domain interaction.

Adeosun SO, Hou X, Zheng B, Stockmeier C, Ou X, Paul I, Mosley T, Weisgraber K, Wang JM.

J Biol Chem. 2014 Jan 31;289(5):2946-59. doi: 10.1074/jbc.M113.497909. Epub 2013 Dec 9.

3.

Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein.

Zhang L, Yan F, Zhang S, Lei D, Charles MA, Cavigiolio G, Oda M, Krauss RM, Weisgraber KH, Rye KA, Pownall HJ, Qiu X, Ren G.

Nat Chem Biol. 2012 Feb 19;8(4):342-9. doi: 10.1038/nchembio.796.

4.

Disease-associated polyglutamine stretches in monomeric huntingtin adopt a compact structure.

Peters-Libeu C, Miller J, Rutenber E, Newhouse Y, Krishnan P, Cheung K, Hatters D, Brooks E, Widjaja K, Tran T, Mitra S, Arrasate M, Mosquera LA, Taylor D, Weisgraber KH, Finkbeiner S.

J Mol Biol. 2012 Aug 24;421(4-5):587-600. doi: 10.1016/j.jmb.2012.01.034. Epub 2012 Jan 28.

5.

Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons.

Chen HK, Liu Z, Meyer-Franke A, Brodbeck J, Miranda RD, McGuire JG, Pleiss MA, Ji ZS, Balestra ME, Walker DW, Xu Q, Jeong DE, Budamagunta MS, Voss JC, Freedman SB, Weisgraber KH, Huang Y, Mahley RW.

J Biol Chem. 2012 Feb 17;287(8):5253-66. doi: 10.1074/jbc.M111.276162. Epub 2011 Dec 12.

6.

Identifying polyglutamine protein species in situ that best predict neurodegeneration.

Miller J, Arrasate M, Brooks E, Libeu CP, Legleiter J, Hatters D, Curtis J, Cheung K, Krishnan P, Mitra S, Widjaja K, Shaby BA, Lotz GP, Newhouse Y, Mitchell EJ, Osmand A, Gray M, Thulasiramin V, Saudou F, Segal M, Yang XW, Masliah E, Thompson LM, Muchowski PJ, Weisgraber KH, Finkbeiner S.

Nat Chem Biol. 2011 Oct 30;7(12):925-34. doi: 10.1038/nchembio.694. Erratum in: Nat Chem Biol. 2012 Mar;8(3):318.

7.

Structure-dependent impairment of intracellular apolipoprotein E4 trafficking and its detrimental effects are rescued by small-molecule structure correctors.

Brodbeck J, McGuire J, Liu Z, Meyer-Franke A, Balestra ME, Jeong DE, Pleiss M, McComas C, Hess F, Witter D, Peterson S, Childers M, Goulet M, Liverton N, Hargreaves R, Freedman S, Weisgraber KH, Mahley RW, Huang Y.

J Biol Chem. 2011 May 13;286(19):17217-26. doi: 10.1074/jbc.M110.217380. Epub 2011 Mar 18.

8.

Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease.

Chen HK, Ji ZS, Dodson SE, Miranda RD, Rosenblum CI, Reynolds IJ, Freedman SB, Weisgraber KH, Huang Y, Mahley RW.

J Biol Chem. 2011 Feb 18;286(7):5215-21. doi: 10.1074/jbc.M110.151084. Epub 2010 Nov 30.

9.

Morphology and structure of lipoproteins revealed by an optimized negative-staining protocol of electron microscopy.

Zhang L, Song J, Cavigiolio G, Ishida BY, Zhang S, Kane JP, Weisgraber KH, Oda MN, Rye KA, Pownall HJ, Ren G.

J Lipid Res. 2011 Jan;52(1):175-84. doi: 10.1194/jlr.D010959. Epub 2010 Oct 26.

10.

Apolipoprotein E expression and purification.

Newhouse Y, Weisgraber KH.

Methods Mol Biol. 2011;670:127-40. doi: 10.1007/978-1-60761-744-0_10.

PMID:
20967588
11.

An optimized negative-staining protocol of electron microscopy for apoE4 POPC lipoprotein.

Zhang L, Song J, Newhouse Y, Zhang S, Weisgraber KH, Ren G.

J Lipid Res. 2010 May;51(5):1228-36. doi: 10.1194/jlr.D002493. Epub 2009 Nov 16.

12.

VLDL lipolysis products increase VLDL fluidity and convert apolipoprotein E4 into a more expanded conformation.

Tetali SD, Budamagunta MS, Simion C, den Hartigh LJ, Kálai T, Hideg K, Hatters DM, Weisgraber KH, Voss JC, Rutledge JC.

J Lipid Res. 2010 Jun;51(6):1273-83. doi: 10.1194/jlr.M000406. Epub 2009 Dec 3.

13.
14.

Apolipoprotein E4 domain interaction induces endoplasmic reticulum stress and impairs astrocyte function.

Zhong N, Ramaswamy G, Weisgraber KH.

J Biol Chem. 2009 Oct 2;284(40):27273-80. doi: 10.1074/jbc.M109.014464. Epub 2009 Aug 7.

15.

Bioactive TGF-beta can associate with lipoproteins and is enriched in those containing apolipoprotein E3.

Tesseur I, Zhang H, Brecht W, Corn J, Gong JS, Yanagisawa K, Michikawa M, Weisgraber K, Huang Y, Wyss-Coray T.

J Neurochem. 2009 Aug;110(4):1254-62. doi: 10.1111/j.1471-4159.2009.06222.x. Epub 2009 Jun 15.

16.

Insight on the molecular envelope of lipid-bound apolipoprotein E from electron paramagnetic resonance spectroscopy.

Hatters DM, Voss JC, Budamagunta MS, Newhouse YN, Weisgraber KH.

J Mol Biol. 2009 Feb 13;386(1):261-71. doi: 10.1016/j.jmb.2008.12.040. Epub 2008 Dec 24.

17.

Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS.

Mahley RW, Weisgraber KH, Huang Y.

J Lipid Res. 2009 Apr;50 Suppl:S183-8. doi: 10.1194/jlr.R800069-JLR200. Epub 2008 Dec 22.

18.

Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure.

Zhong N, Weisgraber KH.

J Biol Chem. 2009 Mar 6;284(10):6027-31. doi: 10.1074/jbc.R800009200. Epub 2008 Oct 22. Review.

19.

Apolipoprotein E4 domain interaction: synaptic and cognitive deficits in mice.

Zhong N, Scearce-Levie K, Ramaswamy G, Weisgraber KH.

Alzheimers Dement. 2008 May;4(3):179-92. doi: 10.1016/j.jalz.2008.01.006.

20.

Genes contributing to prion pathogenesis.

Tamgüney G, Giles K, Glidden DV, Lessard P, Wille H, Tremblay P, Groth DF, Yehiely F, Korth C, Moore RC, Tatzelt J, Rubinstein E, Boucheix C, Yang X, Stanley P, Lisanti MP, Dwek RA, Rudd PM, Moskovitz J, Epstein CJ, Cruz TD, Kuziel WA, Maeda N, Sap J, Ashe KH, Carlson GA, Tesseur I, Wyss-Coray T, Mucke L, Weisgraber KH, Mahley RW, Cohen FE, Prusiner SB.

J Gen Virol. 2008 Jul;89(Pt 7):1777-88. doi: 10.1099/vir.0.2008/001255-0.

21.

Detrimental effects of apolipoprotein E4: potential therapeutic targets in Alzheimer's disease.

Mahley RW, Huang Y, Weisgraber KH.

Curr Alzheimer Res. 2007 Dec;4(5):537-40. Review.

PMID:
18220516
22.

A monomeric, biologically active, full-length human apolipoprotein E.

Zhang Y, Vasudevan S, Sojitrawala R, Zhao W, Cui C, Xu C, Fan D, Newhouse Y, Balestra R, Jerome WG, Weisgraber K, Li Q, Wang J.

Biochemistry. 2007 Sep 18;46(37):10722-32. Epub 2007 Aug 23.

PMID:
17715945
23.

Apolipoprotein E*dipalmitoylphosphatidylcholine particles are ellipsoidal in solution.

Peters-Libeu CA, Newhouse Y, Hall SC, Witkowska HE, Weisgraber KH.

J Lipid Res. 2007 May;48(5):1035-44. Epub 2007 Feb 17.

24.

Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils.

Hatters DM, Zhong N, Rutenber E, Weisgraber KH.

J Mol Biol. 2006 Sep 1;361(5):932-44. Epub 2006 Aug 7.

25.

Human prions and plasma lipoproteins.

Safar JG, Wille H, Geschwind MD, Deering C, Latawiec D, Serban A, King DJ, Legname G, Weisgraber KH, Mahley RW, Miller BL, Dearmond SJ, Prusiner SB.

Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11312-7. Epub 2006 Jul 18.

26.

Apolipoprotein E structure: insights into function.

Hatters DM, Peters-Libeu CA, Weisgraber KH.

Trends Biochem Sci. 2006 Aug;31(8):445-54. Epub 2006 Jul 3. Review.

PMID:
16820298
27.

Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).

Roses AD, Saunders AM, Huang Y, Strum J, Weisgraber KH, Mahley RW.

Pharmacogenomics J. 2007 Feb;7(1):10-28. Epub 2006 Jun 13. Review.

PMID:
16770341
28.

Putting cholesterol in its place: apoE and reverse cholesterol transport.

Mahley RW, Huang Y, Weisgraber KH.

J Clin Invest. 2006 May;116(5):1226-9.

29.

Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease.

Mahley RW, Weisgraber KH, Huang Y.

Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5644-51. Epub 2006 Mar 27. Review.

30.

Intracellular trafficking of recycling apolipoprotein E in Chinese hamster ovary cells.

Braun NA, Mohler PJ, Weisgraber KH, Hasty AH, Linton MF, Yancey PG, Su YR, Fazio S, Swift LL.

J Lipid Res. 2006 Jun;47(6):1176-86. Epub 2006 Mar 13.

31.

Crystallization and diffraction properties of the Fab fragment of 3B5H10, an antibody specific for disease-causing polyglutamine stretches.

Peters-Libeu C, Newhouse Y, Krishnan P, Cheung K, Brooks E, Weisgraber K, Finkbeiner S.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005 Dec 1;61(Pt 12):1065-8. Epub 2005 Nov 24.

32.

Crystallization and preliminary X-ray diffraction analysis of apolipoprotein E-containing lipoprotein particles.

Newhouse Y, Peters-Libeu C, Weisgraber KH.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005 Nov 1;61(Pt 11):981-4. Epub 2005 Oct 20.

33.

Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target.

Ye S, Huang Y, Müllendorff K, Dong L, Giedt G, Meng EC, Cohen FE, Kuntz ID, Weisgraber KH, Mahley RW.

Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18700-5. Epub 2005 Dec 12.

34.

Effect of domain interaction on apolipoprotein E levels in mouse brain.

Ramaswamy G, Xu Q, Huang Y, Weisgraber KH.

J Neurosci. 2005 Nov 16;25(46):10658-63.

35.

Model of biologically active apolipoprotein E bound to dipalmitoylphosphatidylcholine.

Peters-Libeu CA, Newhouse Y, Hatters DM, Weisgraber KH.

J Biol Chem. 2006 Jan 13;281(2):1073-9. Epub 2005 Nov 8.

36.

Modulation of apolipoprotein E structure by domain interaction: differences in lipid-bound and lipid-free forms.

Hatters DM, Budamagunta MS, Voss JC, Weisgraber KH.

J Biol Chem. 2005 Oct 7;280(40):34288-95. Epub 2005 Aug 1.

37.

Diet-induced occlusive coronary atherosclerosis, myocardial infarction, cardiac dysfunction, and premature death in scavenger receptor class B type I-deficient, hypomorphic apolipoprotein ER61 mice.

Zhang S, Picard MH, Vasile E, Zhu Y, Raffai RL, Weisgraber KH, Krieger M.

Circulation. 2005 Jun 28;111(25):3457-64. Epub 2005 Jun 20.

PMID:
15967843
38.

Engineering conformational destabilization into mouse apolipoprotein E. A model for a unique property of human apolipoprotein E4.

Hatters DM, Peters-Libeu CA, Weisgraber KH.

J Biol Chem. 2005 Jul 15;280(28):26477-82. Epub 2005 May 11.

39.

The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor.

Ruiz J, Kouiavskaia D, Migliorini M, Robinson S, Saenko EL, Gorlatova N, Li D, Lawrence D, Hyman BT, Weisgraber KH, Strickland DK.

J Lipid Res. 2005 Aug;46(8):1721-31. Epub 2005 May 1.

40.

Lipoprotein-bound endotoxin exerts an immunomodulatory effect on hepatocytes through the lipid A domain of LPS.

Kasravi FB, Lee DH, Weisgraber K, Harris HW.

J Endotoxin Res. 2005;11(1):19-24.

41.

The recycling of apolipoprotein E in macrophages: influence of HDL and apolipoprotein A-I.

Hasty AH, Plummer MR, Weisgraber KH, Linton MF, Fazio S, Swift LL.

J Lipid Res. 2005 Jul;46(7):1433-9. Epub 2005 Apr 1.

42.

An apolipoprotein E-derived peptide mediates uptake of sterically stabilized liposomes into brain capillary endothelial cells.

Sauer I, Dunay IR, Weisgraber K, Bienert M, Dathe M.

Biochemistry. 2005 Feb 15;44(6):2021-9.

PMID:
15697227
43.

Apolipoprotein E is the major physiological activator of lecithin-cholesterol acyltransferase (LCAT) on apolipoprotein B lipoproteins.

Zhao Y, Thorngate FE, Weisgraber KH, Williams DL, Parks JS.

Biochemistry. 2005 Jan 25;44(3):1013-25.

PMID:
15654758
44.

Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels.

Raffai RL, Loeb SM, Weisgraber KH.

Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):436-41. Epub 2004 Dec 9.

PMID:
15591220
45.

Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease.

Huang Y, Weisgraber KH, Mucke L, Mahley RW.

J Mol Neurosci. 2004;23(3):189-204. Review.

PMID:
15181247
46.

The recycling of apolipoprotein E and its amino-terminal 22 kDa fragment: evidence for multiple redundant pathways.

Farkas MH, Weisgraber KH, Shepherd VL, Linton MF, Fazio S, Swift LL.

J Lipid Res. 2004 Aug;45(8):1546-54. Epub 2004 May 16.

47.

Apolipoprotein E4 domain interaction occurs in living neuronal cells as determined by fluorescence resonance energy transfer.

Xu Q, Brecht WJ, Weisgraber KH, Mahley RW, Huang Y.

J Biol Chem. 2004 Jun 11;279(24):25511-6. Epub 2004 Mar 30.

48.

Induction of cytokine tolerance requires internalization of Chylomicron-Bound LPS into hepatocytes.

Kasravi FB, Brecht WJ, Weisgraber KH, Harris HW.

J Surg Res. 2003 Dec;115(2):303-9.

PMID:
14697298
49.

Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice.

Harris FM, Brecht WJ, Xu Q, Tesseur I, Kekonius L, Wyss-Coray T, Fish JD, Masliah E, Hopkins PC, Scearce-Levie K, Weisgraber KH, Mucke L, Mahley RW, Huang Y.

Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10966-71. Epub 2003 Aug 25.

50.

Antibody phenotyping test for the human apolipoprotein E2 isoform.

Raffaï RL, McPherson R, Weisgraber KH, Innerarity TL, Rassart E, Bersot TP, Milne RW.

Clin Chem. 2003 Sep;49(9):1524-6. No abstract available.

Supplemental Content

Loading ...
Support Center